The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients

Hugo ten Cate*, Anthonie W. A. Lensing, Jeffrey I. Weitz, Saskia Middeldorp, Jan Beyer-Westendorf, Dagmar Kubitza, Timothey Brighton, Gary E. Raskob, Patrick Mismetti, Paolo Prandoni, Martin Gebel, Martin H. Prins

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)75-83
Number of pages9
JournalThrombosis Research
Volume170
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • DEEP-VEIN THROMBOSIS
  • XA INHIBITOR RIVAROXABAN
  • ORAL RIVAROXABAN
  • EINSTEIN-DVT

Cite this